Moderna Inc. shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Heart rate. Blood pressure. Sleep measurements. Blood oxygen levels. Once upon a time, these measurements were usually only ...

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarterOctober 2025 ending cash and cash ...

Johnson & Johnson said on Thursday it has asked U.S. health regulators to authorize its single-dose COVID-19 vaccine for ...

The top U.S. Food and Drug Administration official on Tuesday confirmed AstraZeneca Plc's U.S. COVID-19 vaccine trial is on ...

There's still a lot of confusion around the best time to take a COVID test and where to get them. Here, experts share their ...

The intravenous formulation of fosfomycin has a novel mechanism of action an no known cross-resistance to other antibiotic ...

The most common disease trajectories involved mental illnesses and neurologic, respiratory, and metabolic or digestive ...

The agency might dissuade patients from participating in a crucial part of our research-and-development system.

Through his leadership at the FDA's Center for Biologics Evaluation and Research (CBER), Vinay Prasad, MD, MPH has pushed out at least 7 senior leaders and created an environment that employees worry ...